Two case reports of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy

BACKGROUND: Acquired resistance is inevitable in non-small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). The emergence of EGFR exon 20 C797S is one of the major resistance mechanisms to osimertinib as a third-generation EGFR-T...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Zizheng, Ren, Guanying, Hu, Ling, Wang, Xiaolei, Song, Jin, Jia, Youchao, Zhao, Guofa, Zang, Aimin, Du, Haiwei, Sun, Ying, Zhao, Xiaopeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279785/
https://www.ncbi.nlm.nih.gov/pubmed/35845537
http://dx.doi.org/10.21037/atm-22-2436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279785/
https://www.ncbi.nlm.nih.gov/pubmed/35845537
http://dx.doi.org/10.21037/atm-22-2436

Ejemplares similares